Research at the heart of hematology: thrombocytopenias and platelet function disorders

Balduini, Carlo L.; Melazzini, Federica

doi:10.3324/haematol.2016.158055

Cited by 5 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thrombocytopenia is a pathological condition, often characterized by an abnormally low blood platelet count, which results in an impaired process of stopping bleeding by clumping and clotting blood vessel injuries (Balduini and Melazzini, 2017). In the present study, heparin was used as an agent for an experimental induction of thrombocytopenia.…”

Section: Discussionmentioning

confidence: 97%

“…Thrombocytopenia is a medical condition characterized by an abnormally low platelet count in the blood. Platelets are a component of the blood whose function is to contribute to hemostasis, the process of stopping bleeding by clumping and clotting blood vessel injuries (Balduini and Melazzini, 2017). In thrombocytopenia, the blood has lower levels of platelets, and hence mild to severe bleeding can occur.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of antidote potential of methanol leaf extract of Bauhinia monandra on heparin-induced thrombocytopenia in mice

Nworie¹,

Okorie²,

Ebere³

et al. 2019

bta

View full text Add to dashboard Cite

Thrombocytopenia is closely associated with heparin therapy and hematological disorders and other common diseases in patients admitted in the hospital. Globally, thrombocytopenic cases in hospitals leading to 80% of deaths are mainly due to refractory bleeding and lack of availability of platelet concentrates. Currently, chemical compounds for managing thrombocytopenia are needed. The aim of the study was to determine the effect of methanolic leaf extract of Bauhinia monandra as a potential antidote for treating heparin-induced thrombocytopenia (HIT). A total of 30 mice were used for the experimental study. The mice were divided into five Groups (I-V) of six mice each. Group I (normal control) was given distilled water only, and Group II (positive control) was given heparin only. Groups III, IV, and V (treatment groups) were given heparin and methanolic leaf extract of B. monandra at a dose of 100, 200, and 400 mg/kg body weight (b. wt), respectively. Furthermore, blood samples were collected to determine the blood platelet count. Bleeding time and clotting time were also determined. This study showed that the mice in the group treated with methanolic leaf extract of B. monandra at a dose of 400 mg/kg b. wt had significantly (P < 0.05) higher platelet counts (225.10 ± 6.41) than the control groups: normal control (181.90 ± 11.38) and positive control (127.65 ± 5.79). It also significantly decreased the bleeding and clotting time. Acute toxicity test showed no significant physical and behavioral changes. The results from this study show that leaf methanolic extract of B. monandra is effective as an antidote for treating HIT.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Evaluation of antidote potential of methanol leaf extract of Bauhinia monandra on heparin-induced thrombocytopenia in mice

Nworie¹,

Okorie²,

Ebere³

et al. 2019

bta

View full text Add to dashboard Cite

show abstract

“…Platelets, because of their small size and the limited resolution of early microscopes, escaped identification for a long time, in 1735, the German physician and poet Paul Gottlieb Werlhof provided the first detailed description of 'morbus maculosus haemorrhagicus' now known as immune thrombocytopenia (ITP), these blood cells were unknown [2,3].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Thrombocytopenia in Hematological Malignancies

Sripati

Govindarajan

Ganapathy

2020

JPRI

View full text Add to dashboard Cite

Thrombocytopenia is defined as platelet count < 1.5 lakhs/cumm. It is the commonest platelet abnormality observed in clinical practice with different clinical expression. Thrombocytopenias in hematological malignancies are clonal proliferations of the malignant hematopoietic stem cells characterized by the accumulation of blasts principally in the marrow at the cost of impaired production of normal blood cells. The aim of the present study was to evaluate thrombocytopenia in cases of hematological malignancies with study of clinical profile and laboratory parameters in patients with thrombocytopenia. The present study had maximum numbers of patients were in the age group 20-39 years (8 cases). Patients with platelet count more than 150 x 109/L, patients presented with massive hemorrhage, and who received massive colloid or crystalloid transfusion for volume loss are not included in our study. The maximum number of patients presenting with thrombocytopenia were males (18 cases). It was concluded that chronic lymphocytic leukemia are more common than other hematological malignancy cases.

show abstract

“…Indeed, the irruption of HTS has revolutionized the field of IPDs, leading to identification of many new disorders. 4,14,15,14,15 Our project "Functional and molecular characterization of patients with IPDs" has involved so far 150 patients suspected to have an IPD.The molecular characterization was addressed by Sanger sequencing of candidate genes in the first years, and more recently by HTS.Overall, we have achieved a molecular diagnosis in 80% of cases. This includes a broad representation of classical pathologies, such as BSS, WAS, CAMT, MYH9-RD, GT, HPS or CHS 5,16-18 By means of HTS, we diagnosed a "more novel" type of IPDs in 25% of the patients, includ- Until the end of the last century, we knew only a few forms of inherited thrombocytopenias (ITs) and their main problem was the bleeding tendency, possibly associated with other congenital physical abnormalities.…”

mentioning

confidence: 99%

“…4,[11][12][13] Indeed, the irruption of HTS has revolutionized the field of IPDs, leading to identification of many new disorders. 4,14,15,14,15 Our project "Functional and molecular characterization of patients with IPDs" has involved so far 150 patients suspected to have an IPD. …”

mentioning

confidence: 99%

Speaker Abstracts

2018

Haemophilia

View full text Add to dashboard Cite

Though the treatment options and modalities are constantly improving in the field of haemophilia, we are still not able to entirely prevent joint deterioration and related issues in all persons with haemophilia (PWH). This burden is even more seen in those who suffer from inhibitors. Radiosynovectomy or radiosynoviorthesis (RSO) may not only postpone the need for arthroplasty, but can also significantly decrease pain, recurrent articular bleeding, and thus may improve the quality of life in PWH.Radiosynovectomy is, however, not only "the procedure" done by orthopaedic surgeon. It needs the concert of all multidisciplinary team members taking care of PWH. The respective roles of patient, physiotherapist, nurse, orthopaedic surgeon and haematologist will be discussed during this educational session based on the real case of a patient with severe haemophilia A with inhibitors, who will be also present.Attendees of this session will be encouraged to actively participate in the discussion through answering the questions asked during the presentation (audience interaction will be facilitated through the voting pads available during the session). The development of inhibitory alloantibodies to factor VIII or factor IX is the most serious and challenging complication in haemophilia patients. Previously, on-demand treatment of bleeding episodes in haemophilia persons with inhibitors has shown to be less effective than in patients without inhibitors leading to increased morbidity including more joint disease, negative impact on health-related quality of life (QoL) and increased rate of haemophilia -related deaths. (2) showed a considerable variable responses of prophylaxis outcome as 38% of the persons with more than 50% reduction in bleeding events had no bleeds during the prophylaxis period whereas 38% had less than 50% reduction in bleeding event, implying that there is a rationale for individualized care. Global coagulation assays as thrombin generation assay (TGA) and thromboelastometry might be helpful to optimize prophylactic treatment with bypassing agents to find the optimal product, dose and frequency for each person.Promising prophylactic outcome in inhibitor patients with haemophilia A have also recently been reported from the use of newer treatment principles like emicizumab where prophylaxis resulted in a bleeding rate that was significantly lower (79%) than the rate with previous bypassing-agent prophylaxis (P < .001).Based on the present knowledge prophylaxis should be considered Multicenter projects, such as our project "Functional and molecular characterization of patients with IPDs" under the scientific coverage of the Spanish Society of Thrombosis and Hemostasis, helps these limitations. 5,8Until recently, the molecular diagnosis of IPDs was addressed by sequencing of candidate genes "identified" by the clinical and biological phenotype of the patients. This approach led to molecular diagnosis in less than 50% of patients. Indeed, the irruption of HTS has revolutionized the field of IPDs, leading to i...

show abstract

Research at the heart of hematology: thrombocytopenias and platelet function disorders

Cited by 5 publications

References 16 publications

Evaluation of antidote potential of methanol leaf extract of Bauhinia monandra on heparin-induced thrombocytopenia in mice

Evaluation of antidote potential of methanol leaf extract of Bauhinia monandra on heparin-induced thrombocytopenia in mice

Evaluation of Thrombocytopenia in Hematological Malignancies

Speaker Abstracts

Contact Info

Product

Resources

About